CGT-1967

CGT-1967 is an investigational **oral small-molecule cyclin-dependent kinase inhibitor** being developed by CGeneTech for **hematologic malignancies**, with specific mention of **acute myeloid leukemia** and other **relapsed or refractory blood cancers**. Available context indicates it is formulated as a **tablet** and is being studied in a multicenter, open-label dose-escalation and dose-expansion trial designed to characterize safety, tolerability, pharmacokinetics, dose-limiting toxicities, maximum tolerated dose, and preliminary antitumor activity in patients with relapsed or refractory hematologic cancers. The company pipeline identifies the target broadly as **CDK** and the indication area as **blood cancer**.